These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 11846706)
1. Four years experience of first-trimester nuchal translucency screening for fetal aneuploidies with increasing regional availability. Wayda K; Keresztúri A; Orvos H; Horváth E; PAl A; Kovács L; Szabó J Acta Obstet Gynecol Scand; 2001 Dec; 80(12):1104-9. PubMed ID: 11846706 [TBL] [Abstract][Full Text] [Related]
2. Diagnosis and management of fetal nuchal translucency. Jackson M; Rose NC Semin Roentgenol; 1998 Oct; 33(4):333-8. PubMed ID: 9800243 [TBL] [Abstract][Full Text] [Related]
3. Screening for trisomy 21 in twin pregnancies by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Sebire NJ; Snijders RJ; Hughes K; Sepulveda W; Nicolaides KH Br J Obstet Gynaecol; 1996 Oct; 103(10):999-1003. PubMed ID: 8863698 [TBL] [Abstract][Full Text] [Related]
4. Prenatal screening for fetal aneuploidy in singleton pregnancies. Chitayat D; Langlois S; Douglas Wilson R; ; J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752 [TBL] [Abstract][Full Text] [Related]
5. Fetal nuchal translucency screening in 12495 pregnancies in Sardinia. Zoppi MA; Ibba RM; Floris M; Monni G Ultrasound Obstet Gynecol; 2001 Dec; 18(6):649-51. PubMed ID: 11844208 [TBL] [Abstract][Full Text] [Related]
6. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Snijders RJ; Noble P; Sebire N; Souka A; Nicolaides KH Lancet; 1998 Aug; 352(9125):343-6. PubMed ID: 9717920 [TBL] [Abstract][Full Text] [Related]
7. Screening for fetal aneuploidies and fetal cardiac abnormalities by nuchal translucency thickness measurement at 10-14 weeks of gestation as part of routine antenatal care in an unselected population. Schwärzler P; Carvalho JS; Senat MV; Masroor T; Campbell S; Ville Y Br J Obstet Gynaecol; 1999 Oct; 106(10):1029-34. PubMed ID: 10519427 [TBL] [Abstract][Full Text] [Related]
8. [Prospective cohort study of fetal nuchal translucency in first-trimester and pregnancy outcome]. Tang HR; Zhang Y; Ru T; Li J; Yang L; Xu Y; Duan HL; Wang Y; Wang Y; Hu YL; Zhang Y; Zheng MM Zhonghua Fu Chan Ke Za Zhi; 2020 Feb; 55(2):94-99. PubMed ID: 32146737 [No Abstract] [Full Text] [Related]
10. Ultrasonographic markers for chromosomal abnormalities in women with negative nuchal translucency and second trimester maternal serum biochemistry. Verdin SM; Whitlow BJ; Lazanakis M; Kadir RA; Chatzipapas I; Economides DL Ultrasound Obstet Gynecol; 2000 Oct; 16(5):402-6. PubMed ID: 11169322 [TBL] [Abstract][Full Text] [Related]
11. Screening for trisomy 21 by fetal nuchal translucency and maternal age: a multicenter project in Germany, Austria and Switzerland. Gasiorek-Wiens A; Tercanli S; Kozlowski P; Kossakiewicz A; Minderer S; Meyberg H; Kamin G; Germer U; Bielicki M; Hackelöer BJ; Sarlay D; Kuhn P; Klapp J; Bahlmann F; Pruggmayer M; Schneider KT; Seefried W; Fritzer E; von Kaisenberg CS; Ultrasound Obstet Gynecol; 2001 Dec; 18(6):645-8. PubMed ID: 11844207 [TBL] [Abstract][Full Text] [Related]
12. Screening for chromosomal abnormalities in an unselected population by fetal nuchal translucency. Hafner E; Schuchter K; Philipp K Ultrasound Obstet Gynecol; 1995 Nov; 6(5):330-3. PubMed ID: 8590203 [TBL] [Abstract][Full Text] [Related]
13. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Nicolaides KH Am J Obstet Gynecol; 2004 Jul; 191(1):45-67. PubMed ID: 15295343 [TBL] [Abstract][Full Text] [Related]
14. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience. Spencer K; Nicolaides KH BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267 [TBL] [Abstract][Full Text] [Related]
15. Serum parameters and nuchal translucency in first trimester screening for fetal chromosomal abnormalities. Zimmermann R; Hucha A; Savoldelli G; Binkert F; Achermann J; Grudzinskas JG Br J Obstet Gynaecol; 1996 Oct; 103(10):1009-14. PubMed ID: 8863700 [TBL] [Abstract][Full Text] [Related]
16. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population. Pajkrt E; van Lith JM; Mol BW; Bleker OP; Bilardo CM Ultrasound Obstet Gynecol; 1998 Sep; 12(3):163-9. PubMed ID: 9793187 [TBL] [Abstract][Full Text] [Related]
17. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation. Pandya PP; Snijders RJ; Johnson SP; De Lourdes Brizot M; Nicolaides KH Br J Obstet Gynaecol; 1995 Dec; 102(12):957-62. PubMed ID: 8652486 [TBL] [Abstract][Full Text] [Related]
18. Screening for Down's syndrome by fetal nuchal translucency measurement in a high-risk population. Pajkrt E; Mol BW; van Lith JM; Bleker OP; Bilardo CM Ultrasound Obstet Gynecol; 1998 Sep; 12(3):156-62. PubMed ID: 9793186 [TBL] [Abstract][Full Text] [Related]
19. [Ultrasound screening for Down syndrome and other chromosomal abnormalities by fetal nuchal translucency measurement between 11-14 weeks of gestation]. Dimitrova V; Markov D; Chernev T; Karag'ozova Zh; Mazneĭkova V; Andonova S; Vŭzharova R Akush Ginekol (Sofiia); 2005; 44(1):32-7. PubMed ID: 15853009 [TBL] [Abstract][Full Text] [Related]
20. Measurement of nuchal translucency as a single strategy in trisomy 21 screening: should we use any other marker? Comas C; Torrents M; Muñoz A; Antolín E; Figueras F; Echevarría M Obstet Gynecol; 2002 Oct; 100(4):648-54. PubMed ID: 12383528 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]